Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Stock Sees Buying Interest After The News
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) jumped 8%after announcing that the US FDA’s Pulmonary, Allergy, and Critical Care Division had approved its Investigational New Drug application for its flagship drug candidate, trans sodium crocetinate (TSC). Currently, the company has open TSC INDs with 4 FDA divisions, including Cardiology and Nephrology, Pulmonary, Allergy and Critical Care, Oncology and Neurology that the company believes will support the product candidate’s wide therapeutic potential. The company…